Ethical Concerns about Psilocybin Intellectual Property.

Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.
Competing Interests: The authors declare no competing financial interest.
(© 2021 American Chemical Society.)